-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target

Benzinga·03/27/2026 12:47:09
Listen to the news
Guggenheim analyst Michael Schmidt reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $6 price target.